Biological treatments in Behçet's disease: beyond anti-TNF therapy. (Q33908217)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2 references

1 February 2021

28 October 2022

Biological treatments in Behçet's disease: beyond anti-TNF therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

0 references

10 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

1 August 2019

3 October 2019

20 November 2019

27 November 2019

Tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

20 November 2019

1 reference

27 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Orso Maria Lucherini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Luca Cantarini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Luisa Costa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Donato Rigante

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Edoardo Marrani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Leonardo Punzi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

8

Rolando Cimaz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

7

Bruno Frediani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

5

Paolo Caso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

6

Vittoria Bascherini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

11

Mariangela Atteno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

14

Mauro Galeazzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

13

Giusyda Tarantino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Laura Nieves-Martín

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Carmela G L Raffaele

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

30 June 2014

13 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

1 August 2019

3 October 2019

20 November 2019

27 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 February 2021

28 October 2022

Mediators of Inflammation

13 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

1 August 2019

3 October 2019

20 November 2019

27 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 February 2021

28 October 2022

2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

107421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

10 March 2020

copyright license

12 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

1 August 2019

3 October 2019

20 November 2019

27 November 2019

1 February 2021

on focus list of Wikimedia project

28 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Improved clinical control of a challenging case of Behçet's disease with rituximab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Treating inflammation by blocking interleukin-1 in humans

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Biological treatments: new weapons in the management of monogenic autoinflammatory disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Inflammasome and cytokine blocking strategies in autoinflammatory disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

New insights into the pathogenesis of Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

The fresco of autoinflammatory diseases from the pediatric perspective

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Infliximab for patients with neuro-Behcet's disease: case series and literature review.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Major vessel involvement in Behçet's disease: an update

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Genetic susceptibility to Behcet's disease: role of genes belonging to the MHC region

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Interferon therapy in rheumatic diseases: state-of-the-art 2010.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Interleukin-6 as a key player in systemic inflammation and joint destruction.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Neuro-Behçet's disease: epidemiology, clinical characteristics, and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Treatment of retinal vasculitis in Behçet's disease with rituximab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

EULAR recommendations for the management of Behçet disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

A double-blind trial of colchicine in Behçet's syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Intravenous immunoglobulin therapy for resistant ocular Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Use of rituximab, the new FDA-approved antibody.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Azathioprine in Behcet's syndrome: effects on long-term prognosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

A controlled trial of azathioprine in Behçet's syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

5 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Pulmonary artery aneurysms in Behçet syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Upregulated IL-23 and IL-17 in Behçet patients with active uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Efficacy and tolerability of rituximab in patients with rhupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

A beneficial effect of rituximab on autoimmune thrombotic thrombocytopenic purpura: just a B-cell depletion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Anakinra for resistant Behçet uveitis: why not?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Cytokines and Behcet's disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Resistant Behçet disease responsive to anakinra

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

29 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F107421

Efficacy of anakinra in refractory Behçet's disease sacroiliitis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Successful use of canakinumab in a patient with resistant Behçet's disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4100257

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

29 October 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis?

1 reference

12 December 2020

Cytokine profile in Behçet's disease patients. Relationship with disease activity

1 reference

12 December 2020

Refractory neuro-Behçet treated by tocilizumab: a case report

1 reference

12 December 2020

Production of TNF-alpha and IL-1 in active Behçet's disease

1 reference

12 December 2020

A double blind study of colchicine in Behçet's disease

1 reference

12 December 2020

Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet's disease

1 reference

12 December 2020

Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behçet's disease

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets

1 reference

12 December 2020

Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome

1 reference

12 December 2020

Identifiers

DOI

10.1155/2014/107421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25061259%20AND%20SRC:MED&resulttype=core&format=json